A phase 3 study of ravulizumab to protect patients with chronic kidney disease from cardiac surgery-associated acute kidney injury and major adverse kidney events (ARTEMIS)

A phase 3 study of ravulizumab to protect patients with chronic kidney disease from cardiac surgery-associated acute kidney injury and major adverse kidney events (ARTEMIS)

Abstract Background Cardiac procedures, particularly those requiring cardiopulmonary bypass (CPB), are associated with the development of cardiac surgery-associated acute kidney injury (CSA-AKI). Development of CSA-AKI occurs as a result of inflammation, uncontrolled complement activation, and kidne...

Full description

Saved in:
Bibliographic Details
Main Authors: Marlies Ostermann, David C. Corteville, Kent Doi, Jay L. Koyner, Andre Lamy, Gerry Li, Christine M. Solinsky, Pamela D. Winterberg, William T. Smith, Ravindra L. Mehta, Patrick T. Murray, Andrew D. Shaw, Alexander Zarbock, Daniel T. Engelman
Format: Article
Language:English
Published: BMC 2025-05-01
Series:Trials
Subjects:
Cardiac surgery-associated acute kidney injury
Cardiopulmonary bypass
Chronic kidney disease
Complement activation
Interventional study
Ischemia–reperfusion injury
Online Access:https://doi.org/10.1186/s13063-025-08895-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13063-025-08895-7

Similar Items